{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000044","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.222003+00:00","generated_at":"2026-05-31T01:56:17.901257+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mineralys completes enrollment of 261 subjects in pivotal Advance-HTN trial; topline Q1 2025","bullets":["Target enrollment of 261 subjects achieved in Phase 2 Advance-HTN trial of lorundrostat for uncontrolled or resistant hypertension.","Topline data expected Q1 2025; additional subjects in screening may enroll over next several weeks.","Trial is randomized, double-blind, placebo-controlled, add-on to standardized antihypertensive regimen.","Virtual KOL event scheduled for October 30, 2024 to discuss unmet need and clinical program."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000044","json":"https://secwatch.observer/filing/0001933414-24-000044.json","markdown":"https://secwatch.observer/filing/0001933414-24-000044.md","text":"https://secwatch.observer/filing/0001933414-24-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000044/0001933414-24-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000044/mlys-20240925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:56:17.901257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}